비호지킨 림프종에서 DNA Topoisomerase II , Ki-67, p53 및 p27 발현변화
Altered Expression of DNA Topoisomerase II , Ki-67, p53 and p27 in Non-Hodgkin’s Lymphoma
이경민, 김활웅, 설미영, 김지연, 신동훈, 최경운, 이창훈, 박도윤, 강현정,
소속 상세정보
이경민 ( Lee Kyeong-Min )
부산대학교 의과대학 병리학교실
김활웅 ( Kim Hwal-Woong )
부산대학교 의과대학 병리학교실
설미영 ( Sol Mi-Young )
부산대학교 의과대학 병리학교실
김지연 ( Kim Jee-Yeon )
부산대학교 의과대학 병리학교실
신동훈 ( Shin Dong-Hoon )
부산대학교 의과대학 병리학교실
최경운 ( Choi Kyung-Un )
부산대학교 의과대학 병리학교실
이창훈 ( Lee Chang-Hun )
부산대학교 의과대학 병리학교실
박도윤 ( Park Do-Youn )
부산대학교 의과대학 병리학교실
강현정 ( Kang Hyun-Jeong )
부산대학교 의과대학 병리학교실
KMID : 0357920050390050332
Abstract
Background: Topoisomerase II (TOPO II) is an enzyme that separates intertwined chromosomes during DNA synthesis by transiently breaking and joining DNA strands. The level of TOP II is one of the determinants of cellular sensitivity to anti-tumor drugs in non-Hodgkin’s lymphoma patients. The alpha form of TOPO II has been recently used as a marker of cellular proliferation. High levels of TOPO II are expressed in aggressive and proliferative tumors.
Methods: This study was designed to evaluate the relationship between TOPO II expression and clinicopathological parameters including age, gender, the serum LDH level, the serum 2-microglobulin level and stage, or expressions, of Ki-67, p53 and p27, in non-Hodgkin’s lymphoma. We analyzed forty-one biopsied tissue specimens from patients with non-Hodgkin’s lymphoma.
Results: The expression of TOPO II increased with the clinical stage and it was correlated with Ki-67 and p53 expressions. However, TOPO II expression did not have any significant correlation with age, gender, the serum LDH level, the serum 2-mcroglobulin level and the p27 expression.
Conclusions: TOPO II expression is a useful marker of cellular proliferation and it may serve as a prognostic factor of a tumor’s progression and aggressiveness in non-Hodgkin’s lymphomas.
키워드
Non-Hodgkin’s lymphoma;Topoisomerase II;Protein p53;Ki-67 antigen;p27 antigen
원문 및 링크아웃 정보
등재저널 정보